Sildenafil for chronic obstructive pulmonary disease

A randomized crossover trial

David J. Lederer, Matthew N. Bartels, Neil W. Schluger, Frances Brogan, Patricia Jellen, Byron M. Thomashow, Steven M. Kawut

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

Rationale: Pulmonary hypertension with exercise is common in chronic obstructive pulmonary disease (COPD) and may contribute to exercise limitation in this disease. We aimed to determine the effects of treatment with sildenafil on exercise capacity in patients with COPD and emphysema. Methods: We performed a randomized, double-blind, placebo-controlled 2-period crossover trial of sildenafil thrice daily in ten adults with COPD and emphysema on CT scan without pulmonary hypertension. We randomized study participants to 4 weeks of sildenafil (or placebo) followed by a 1-week washout and then 4 weeks of placebo (or sildenafil). The 2 primary outcomes were the 6-minute walk distance and oxygen consumption at peak exercise. Results: Sildenafil had no effect on 6-minute walk distance (placebo-corrected difference = -7.8 m, 95% confidence interval, -23.2 to 7.5 m, p = 0.35) or oxygen consumption at peak exercise (placebo-corrected difference = -0.1 ml/kg/min, 95 confidence interval -2.1 to 1.8 ml/kg/min, p = 0.89). Sildenafil increased the alveolar-arterial oxygen gradient (p = 0.02), worsened symptoms (p = 0.04), and decreased quality-of-life (p = 0.03). Adverse events were more frequent while receiving sildenafil (p = 0.005). Conclusions: Routine sildenafil administration did not have a beneficial effect on exercise capacity in patients with COPD and emphysema without pulmonary hypertension. Sildenafil significantly worsened gas exchange at rest and quality of life.

Original languageEnglish (US)
Pages (from-to)268-275
Number of pages8
JournalCOPD: Journal of Chronic Obstructive Pulmonary Disease
Volume9
Issue number3
DOIs
StatePublished - Jun 2012
Externally publishedYes

Fingerprint

Cross-Over Studies
Chronic Obstructive Pulmonary Disease
Exercise
Pulmonary Emphysema
Placebos
Pulmonary Hypertension
Oxygen Consumption
Quality of Life
Confidence Intervals
Sildenafil Citrate
Gases
Oxygen

Keywords

  • Clinical Trial
  • COPD
  • Emphysema
  • Pulmonary hypertension.
  • Sildenafil

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Sildenafil for chronic obstructive pulmonary disease : A randomized crossover trial. / Lederer, David J.; Bartels, Matthew N.; Schluger, Neil W.; Brogan, Frances; Jellen, Patricia; Thomashow, Byron M.; Kawut, Steven M.

In: COPD: Journal of Chronic Obstructive Pulmonary Disease, Vol. 9, No. 3, 06.2012, p. 268-275.

Research output: Contribution to journalArticle

Lederer, David J. ; Bartels, Matthew N. ; Schluger, Neil W. ; Brogan, Frances ; Jellen, Patricia ; Thomashow, Byron M. ; Kawut, Steven M. / Sildenafil for chronic obstructive pulmonary disease : A randomized crossover trial. In: COPD: Journal of Chronic Obstructive Pulmonary Disease. 2012 ; Vol. 9, No. 3. pp. 268-275.
@article{4eecf7bce2764bfb92896b5e0ce0d335,
title = "Sildenafil for chronic obstructive pulmonary disease: A randomized crossover trial",
abstract = "Rationale: Pulmonary hypertension with exercise is common in chronic obstructive pulmonary disease (COPD) and may contribute to exercise limitation in this disease. We aimed to determine the effects of treatment with sildenafil on exercise capacity in patients with COPD and emphysema. Methods: We performed a randomized, double-blind, placebo-controlled 2-period crossover trial of sildenafil thrice daily in ten adults with COPD and emphysema on CT scan without pulmonary hypertension. We randomized study participants to 4 weeks of sildenafil (or placebo) followed by a 1-week washout and then 4 weeks of placebo (or sildenafil). The 2 primary outcomes were the 6-minute walk distance and oxygen consumption at peak exercise. Results: Sildenafil had no effect on 6-minute walk distance (placebo-corrected difference = -7.8 m, 95{\%} confidence interval, -23.2 to 7.5 m, p = 0.35) or oxygen consumption at peak exercise (placebo-corrected difference = -0.1 ml/kg/min, 95 confidence interval -2.1 to 1.8 ml/kg/min, p = 0.89). Sildenafil increased the alveolar-arterial oxygen gradient (p = 0.02), worsened symptoms (p = 0.04), and decreased quality-of-life (p = 0.03). Adverse events were more frequent while receiving sildenafil (p = 0.005). Conclusions: Routine sildenafil administration did not have a beneficial effect on exercise capacity in patients with COPD and emphysema without pulmonary hypertension. Sildenafil significantly worsened gas exchange at rest and quality of life.",
keywords = "Clinical Trial, COPD, Emphysema, Pulmonary hypertension., Sildenafil",
author = "Lederer, {David J.} and Bartels, {Matthew N.} and Schluger, {Neil W.} and Frances Brogan and Patricia Jellen and Thomashow, {Byron M.} and Kawut, {Steven M.}",
year = "2012",
month = "6",
doi = "10.3109/15412555.2011.651180",
language = "English (US)",
volume = "9",
pages = "268--275",
journal = "COPD: Journal of Chronic Obstructive Pulmonary Disease",
issn = "1541-2555",
publisher = "Informa Healthcare",
number = "3",

}

TY - JOUR

T1 - Sildenafil for chronic obstructive pulmonary disease

T2 - A randomized crossover trial

AU - Lederer, David J.

AU - Bartels, Matthew N.

AU - Schluger, Neil W.

AU - Brogan, Frances

AU - Jellen, Patricia

AU - Thomashow, Byron M.

AU - Kawut, Steven M.

PY - 2012/6

Y1 - 2012/6

N2 - Rationale: Pulmonary hypertension with exercise is common in chronic obstructive pulmonary disease (COPD) and may contribute to exercise limitation in this disease. We aimed to determine the effects of treatment with sildenafil on exercise capacity in patients with COPD and emphysema. Methods: We performed a randomized, double-blind, placebo-controlled 2-period crossover trial of sildenafil thrice daily in ten adults with COPD and emphysema on CT scan without pulmonary hypertension. We randomized study participants to 4 weeks of sildenafil (or placebo) followed by a 1-week washout and then 4 weeks of placebo (or sildenafil). The 2 primary outcomes were the 6-minute walk distance and oxygen consumption at peak exercise. Results: Sildenafil had no effect on 6-minute walk distance (placebo-corrected difference = -7.8 m, 95% confidence interval, -23.2 to 7.5 m, p = 0.35) or oxygen consumption at peak exercise (placebo-corrected difference = -0.1 ml/kg/min, 95 confidence interval -2.1 to 1.8 ml/kg/min, p = 0.89). Sildenafil increased the alveolar-arterial oxygen gradient (p = 0.02), worsened symptoms (p = 0.04), and decreased quality-of-life (p = 0.03). Adverse events were more frequent while receiving sildenafil (p = 0.005). Conclusions: Routine sildenafil administration did not have a beneficial effect on exercise capacity in patients with COPD and emphysema without pulmonary hypertension. Sildenafil significantly worsened gas exchange at rest and quality of life.

AB - Rationale: Pulmonary hypertension with exercise is common in chronic obstructive pulmonary disease (COPD) and may contribute to exercise limitation in this disease. We aimed to determine the effects of treatment with sildenafil on exercise capacity in patients with COPD and emphysema. Methods: We performed a randomized, double-blind, placebo-controlled 2-period crossover trial of sildenafil thrice daily in ten adults with COPD and emphysema on CT scan without pulmonary hypertension. We randomized study participants to 4 weeks of sildenafil (or placebo) followed by a 1-week washout and then 4 weeks of placebo (or sildenafil). The 2 primary outcomes were the 6-minute walk distance and oxygen consumption at peak exercise. Results: Sildenafil had no effect on 6-minute walk distance (placebo-corrected difference = -7.8 m, 95% confidence interval, -23.2 to 7.5 m, p = 0.35) or oxygen consumption at peak exercise (placebo-corrected difference = -0.1 ml/kg/min, 95 confidence interval -2.1 to 1.8 ml/kg/min, p = 0.89). Sildenafil increased the alveolar-arterial oxygen gradient (p = 0.02), worsened symptoms (p = 0.04), and decreased quality-of-life (p = 0.03). Adverse events were more frequent while receiving sildenafil (p = 0.005). Conclusions: Routine sildenafil administration did not have a beneficial effect on exercise capacity in patients with COPD and emphysema without pulmonary hypertension. Sildenafil significantly worsened gas exchange at rest and quality of life.

KW - Clinical Trial

KW - COPD

KW - Emphysema

KW - Pulmonary hypertension.

KW - Sildenafil

UR - http://www.scopus.com/inward/record.url?scp=84862087261&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862087261&partnerID=8YFLogxK

U2 - 10.3109/15412555.2011.651180

DO - 10.3109/15412555.2011.651180

M3 - Article

VL - 9

SP - 268

EP - 275

JO - COPD: Journal of Chronic Obstructive Pulmonary Disease

JF - COPD: Journal of Chronic Obstructive Pulmonary Disease

SN - 1541-2555

IS - 3

ER -